Any feedback?
Information on EC 2.8.2.17 - chondroitin 6-sulfotransferase and Organism(s) Homo sapiens and UniProt Accession Q9NS84
for references in articles please use BRENDA:EC2.8.2.17Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.8.2.17 chondroitin 6-sulfotransferaseIUBMB Comments
The sulfation is at the 6-position of N-acetylgalactosamine residues of chondroitin. Not identical with EC 2.8.2.5 chondroitin 4-sulfotransferase.
Specify your search results
Word Map
- 2.8.2.17
-
sulfotransferases
- proteoglycans
- glycosaminoglycans
- n-acetylgalactosamine
- keratan
- 6-sulfate
-
spondyloepiphyseal
-
4-sulfotransferase
-
6-o-sulfated
-
omani
-
2-o-sulfotransferase
-
chst15
-
uronyl
-
kyphoscoliosis
-
larsen
-
6-sulphated
- medicine
- synthesis
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
chst3, c6st, c6st-1, chondroitin 6-sulfotransferase, carbohydrate sulfotransferase 3, c6st1, chondroitin 6-o-sulfotransferase-1, chondroitin 6-o-sulfotransferase, chondroitin-6-sulfotransferase, chondroitin 6-sulfotransferase-1, 
more
topSYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
3'-phosphoadenosine 5'-phosphosulfate:chondroitin sulfate sulfotransferase
-
-
-
-
C6ST
-
-
-
-
chondroitin 6-O-sulfotransferase
-
-
-
-
CST
-
-
-
-
sulfotransferase, chondroitin 6-
-
-
-
-
terminal 6-sulfotransferase
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
sulfate group transfer
-
-
-
-
PATHWAY SOURCE
PATHWAYS
-
-
SYSTEMATIC NAME
IUBMB Comments
3'-phosphoadenylyl-sulfate:chondroitin 6'-sulfotransferase
The sulfation is at the 6-position of N-acetylgalactosamine residues of chondroitin. Not identical with EC 2.8.2.5 chondroitin 4-sulfotransferase.
CAS REGISTRY NUMBER
COMMENTARY
37292-93-6
-
83589-04-2
-
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
incorporates sulfate exclusively into GalNAc C-6 position
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
24% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
270% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
260% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal-Gal(6S)beta(1->4)Xyl-ol
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xyl-ol
360% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl(2P)-ol
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)-Galbeta(1->4)Xyl(2P)-ol
290% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->4)GlcNAc(6S)-GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->4)GlcNAc(6S)beta(1->3)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
17% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
4% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GalNAcbeta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
84% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcNAcalpha(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcNAcalpha(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
2% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
20% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
8% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
250% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)GalNAcbeta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)GalNAc(6S)beta(1->3)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
130% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylylsulfate + beta-benzyl N-acetylglucosamine
adenosine 3',5'-bisphosphate + beta-benzyl N-acetylglucosaminesulfate
-
enzyme does not use alpha-or beta-benzyl N-acetylgalactosamine
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin sulfate A
adenosine 3',5'-bisphosphate + ?
-
6.2% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + chondroitin sulfate C
adenosine 3',5'-bisphosphate + ?
-
3% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
transfers sulfate to position 6 of Gal residues
-
-
?
3'-phosphoadenylylsulfate + desulfated dermatan sulfate
adenosine 3',5'-bisphosphate + ?
-
95% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + phenyl 2-acetamido-2-deoxy-4-O-sulfonato-D-galactopyranose
adenosine 3',5'-bisphosphate + phenyl 2-acetamido-2-deoxy-4,6-di-O-sulfonato-D-galactopyranose
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
incorporates sulfate exclusively into GalNAc C-6 position
-
-
?
additional information
?
-
keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc sequence hardly serve as acceptors for C6ST-2
-
-
?
additional information
?
-
-
keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc sequence hardly serve as acceptors for C6ST-2
-
-
?
additional information
?
-
overview: sulfation of chondroitin sulfates
-
-
?
additional information
?
-
-
no substrate: dermatan sulfate. Enzyme mainly transfers sulfate to GalNAc residues located in the L-iduronic acid rich region with little preference for the GalNAc residue neighbouring the GlcA residue
-
-
?
additional information
?
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
additional information
?
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
phenyl 2-acetamido-2-deoxy-4-O-sulfonato-D-galactopyranose
-
competitive, 5 mM, 76% inhibition, specific
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.05
GlcUAbeta(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
pH 6.8, 37°C
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
from surgical disc procedures performed on individuals with herniated discs and degenerative disc disease
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
physiological function
key molecules promoting migration and invasion exist in the extracellular matrix, and include chondroitin 4-sulfate (C4S) and chondroitin 6-sulfate (C6S), functionally important carbohydrate chains of chondroitin sulfate proteoglycans that participate in regulating cancer development. The C4S- and C6S-enhanced epithelial-tomesenchymal transition and expression of MMP-2 occur via activation of the PI3K/AKT signaling pathway, known to be involved in promoting cell migration and invasion. C4S and C6S increase the numbers of living glioma cells and promote proliferation, they promote colony formation of glioma cells, phenotypes, overview
malfunction
deficiency of CHST3 is associated with a phenotype of severe chondrodysplasia with progressive spinal involvement
malfunction
Omani-type spondyloepiphyseal dysplasia with cardiac involvement caused by a missense mutation in CHST3
malfunction
C6ST-1 activity and C6S production are upregulated in human glioma tissues, when compared to normal brain tissue, and the extent of upregulation positively correlates with glioma malignancy. Inhibition of expression of the two CS synthetic enzymes chondroitin 4-O-sulfotransferase-1 (C4ST-1/CHST11, EC 2.8.2.5) and chondroitin 6-O-sulfotransferase-1 (C6ST-1/CHST3) suppress cell viability, migration and invasion, reduce MMP-2 and MMP-9 expression, and reduce N-cadherin expression, but increase E-cadherin levels. Clinicopathological features, overview
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). CHST7_HUMAN
486
1
54266
Swiss-Prot
Secretory Pathway (Reliability: 1)
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
L259P
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
L286P
naturally occuring mutation of gene CHST3 causing the Spondyloepiphyseal dysplasia Omani type, almost inactive mutant, phenotype, overview
L307P
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
R222W
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
R304Q
T141M
homozygous missense mutation leading to a reduction of C6ST-1 activity to 24-29% of the wild type enzyme, the naturally occuring missense mutation in exon 3 of gene CHST3 causes Omani-type spondyloepiphyseal dysplasia with cardiac involvement, phenotype with skeletal features, cardiac involvement including mitral, tricuspid and/or aortic regurgitations and type E brachydactyly, overview
additional information
R304Q
-
missense mutation found in patients with a distinct form of spondyloepiphyseal dysplasia, SED Omani type, complete loss of activity, resulting in significant reduction of both DELTAHexA-GalNAc(6S) and DELTAHexA(2S)-GalNAc(6S) and elevate levels of DELTAHexA-GalNAc(4S,6S)
R304Q
naturally occuring mutation of gene CHST3 causing the Spondyloepiphyseal dysplasia Omani type, phenotype, overview
additional information
identification of eight naturally occuring CHST3 mutations in six unrelated individuals who presented at birth with congenital joint dislocations with diagnosis of either Larsen syndrome or humero-spinal dysostosis, the patients show reduced enzyme activity and congenital dislocation of the knees, elbow joint dysplasia with subluxation and limited extension, hip dysplasia or dislocation, clubfoot, short stature, and kyphoscoliosis developing in late childhood, genotyping, enzyme mutant phenotypes, overview
additional information
-
identification of eight naturally occuring CHST3 mutations in six unrelated individuals who presented at birth with congenital joint dislocations with diagnosis of either Larsen syndrome or humero-spinal dysostosis, the patients show reduced enzyme activity and congenital dislocation of the knees, elbow joint dysplasia with subluxation and limited extension, hip dysplasia or dislocation, clubfoot, short stature, and kyphoscoliosis developing in late childhood, genotyping, enzyme mutant phenotypes, overview
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
gene CHST3, expression of wild-type enzyme and mutant L286P in COS-7 cells as soluble FLAG-tagged proteins
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
-
missense mutation R304Q found in patients with a distinct form of spondyloepiphyseal dysplasia, SED Omani type, leads to complete loss of activity, resulting in significant reduction of both DELTAHexA-GalNAc(6S) and DELTAHexA(2S)-GalNAc(6S) and elevated levels of DELTAHexA-GalNAc(4S,6S). Defect in chondroitin sulfate chain sulfation results in chondrodysplasia with major involvement of the spine
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Bhakta, S.; Bartes, A.; Bowman, K.G.; Kao, W.M.; Polsky, I.; Lee, J.K.; Cook, B.N.; Bruehl, R.E.; Rosen, S.D.; Bertozzi, C.R.; Hemmerich, S.
Sulfation of N-acetylglucosamine by chondroitin 6-sulfotransferase 2 (GST-5)
J. Biol. Chem.
275
40226-40234
2000
Homo sapiens, Mus musculus (Q9EP78), Mus musculus
Fukuta, M.; Kobayashi, Y.; Uchimura, K.; Kimata, K.; Habuchi, O.
Molecular cloning and expression of human chondroitin 6-sulfotransferase
Biochim. Biophys. Acta
1399
57-61
1998
Homo sapiens (Q7LGC8), Homo sapiens
Kitagawa, H.; Fujita, M.; Ito, N.; Sugahara, K.
Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase
J. Biol. Chem.
275
21075-21080
2000
Homo sapiens (Q9NS84), Homo sapiens
Tsutsumi, K.; Shimakawa, H.; Kitagawa, H.; Sugahara, K.
Functional expression and genomic structure of human chondroitin 6-sulfotransferase
FEBS Lett.
441
235-241
1998
Homo sapiens (Q7LGC8), Homo sapiens
Sawada, T.; Fujii, S.; Nakano, H.; Ohtake, S.; Kimata, K.; Habuchi, O.
Synthesis of sulfated phenyl 2-acetamido-2-deoxy-D-galactopyranosides. 4-O-Sulfated phenyl 2-acetamido-2-deoxy-beta-D-galactopyranoside is a competitive acceptor that decreases sulfation of chondroitin sulfate by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase
Carbohydr. Res.
340
1983-1996
2005
Homo sapiens
Yamada, T.; Ohtake, S.; Sato, M.; Habuchi, O.
Chondroitin 4-sulphotransferase-1 and chondroitin 6-sulphotransferase-1 are affected differently by uronic acid residues neighbouring the acceptor GalNAc residues
Biochem. J.
384
567-575
2004
Homo sapiens
Thiele, H.; Sakano, M.; Kitagawa, H.; Sugahara, K.; Rajab, A.; Hoehne, W.; Ritter, H.; Leschik, G.; Nuernberg, P.; Mundlos, S.
Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement
Proc. Natl. Acad. Sci. USA
101
10155-10160
2004
Homo sapiens
Gruber, H.E.; Ingram, J.; Leslie, K.; Hanley, E.N.
Gene expression of types I, II, and VI collagen, aggrecan, and chondroitin-6-sulfotransferase in the human annulus: in situ hybridization findings
Spine J.
8
810-817
2008
Homo sapiens
Hermanns, P.; Unger, S.; Rossi, A.; Perez-Aytes, A.; Cortina, H.; Bonafe, L.; Boccone, L.; Setzu, V.; Dutoit, M.; Sangiorgi, L.; Pecora, F.; Reicherter, K.; Nishimura, G.; Spranger, J.; Zabel, B.; Superti-Furga, A.
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis
Am. J. Hum. Genet.
82
1368-1374
2008
Homo sapiens (Q7LGC8), Homo sapiens
van Roij, M.H.; Mizumoto, S.; Yamada, S.; Morgan, T.; Tan-Sindhunata, M.B.; Meijers-Heijboer, H.; Verbeke, J.I.; Markie, D.; Sugahara, K.; Robertson, S.P.
Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype
Am. J. Med. Genet. A
146A
2376-2384
2008
Homo sapiens (Q7LGC8), Homo sapiens
Tuysuz, B.; Mizumoto, S.; Sugahara, K.; Celebi, A.; Mundlos, S.; Turkmen, S.
Omani-type spondyloepiphyseal dysplasia with cardiac involvement caused by a missense mutation in CHST3
Clin. Genet.
75
375-383
2009
Homo sapiens (Q7LGC8)
Kitagawa, H.; Tsutsumi, K.; Ikegami-Kuzuhara, A.; Nadanaka, S.; Goto, F.; Ogawa, T.; Sugahara, K.
Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase-1
J. Biol. Chem.
283
27438-27443
2008
Homo sapiens (Q7LGC8), Homo sapiens
EXTERNAL LINKS (specific for EC-Number 2.8.2.17)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
